Italia markets open in 4 hours 56 minutes

Novartis AG (NOVN.SW)

Swiss - Swiss Prezzo differito. Valuta in CHF.
Aggiungi a portafoglio
76,32-0,61 (-0,79%)
Alla chiusura: 5:31PM CEST
Schermo intero
Chiusura precedente76,93
Aperto76,83
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno75,96 - 76,99
Intervallo di 52 settimane70,42 - 86,92
Volume2.197.289
Media Volume3.365.856
Capitalizzazione170,708B
Beta (5 anni mensile)0,55
Rapporto PE (ttm)20,92
EPS (ttm)3,65
Prossima data utili26 ott 2021
Rendimento e dividendo (forward)3,00 (3,90%)
Data ex dividendo04 mar 2021
Stima target 1A93,85
  • GlobeNewswire

    Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

    Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotic

  • GlobeNewswire

    Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

    Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regard

  • GlobeNewswire

    Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

    Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in health outcomesContinued our global health leadership with positive phase 2b results for our next generation antimalarial therapy ganaplacide in combination with lumefantrine which support its continued developmentCommitted to achieving net zero car